



# Corrigendum: Identification of *BRCA1:c.5470\_5477del* as a Founder Mutation in Chinese Ovarian Cancer Patients

Jun Li<sup>1,2†</sup>, Sile Han<sup>1†</sup>, Cuiyun Zhang<sup>1,2</sup>, Yanlin Luo<sup>3</sup>, Li Wang<sup>3</sup>, Ping Wang<sup>4</sup>, Yi Wang<sup>5</sup>, Qingxin Xia<sup>5</sup>, Xiaoyan Wang<sup>1,2</sup>, Bing Wei<sup>1,2</sup>, Jie Ma<sup>1,2</sup>, Hongle Li<sup>1,2\*</sup> and Yongjun Guo<sup>1,2\*</sup>

## OPEN ACCESS

### Approved by:

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

### \*Correspondence:

Yongjun Guo  
guoyongjun@zzu.edu.cn  
Hongle Li  
llh173@163.com

<sup>†</sup>These authors have contributed  
equally to this work and share first  
authorship

### Specialty section:

This article was submitted to  
Gynecological Oncology,  
a section of the journal  
Frontiers in Oncology

**Received:** 21 December 2021

**Accepted:** 22 December 2021

**Published:** 14 January 2022

### Citation:

Li J, Han S, Zhang C, Luo Y,  
Wang L, Wang P, Wang Y,  
Xia Q, Wang X, Wei B, Ma J, Li H  
and Guo Y (2022) Corrigendum:  
Identification of *BRCA1*:  
*c.5470\_5477del* as a Founder  
Mutation in Chinese Ovarian  
Cancer Patients.  
*Front. Oncol.* 11:840551.  
doi: 10.3389/fonc.2021.840551

<sup>1</sup> Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, <sup>2</sup> Henan Key Laboratory of Molecular Pathology, Zhengzhou, China, <sup>3</sup> Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China, <sup>4</sup> Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China, <sup>5</sup> Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

**Keywords:** *BRCA1/2*, haplotype analysis, ovarian cancer, founder mutation, Chinese

## A Corrigendum on:

### Identification of *BRCA1: c.5470\_5477del* as a Founder Mutation in Chinese Ovarian Cancer Patients

by Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2021). *Front. Oncol.* 11:655709. doi: 10.3389/fonc.2021.655709

In the original article, we neglected to include the funder National Natural Science Foundation of China, 81802779 to Jun Li; Henan Provincial Health Commission, SBGJ202002020 to Jun Li; and Henan Science and Technology Project, 212102310675 to Jun Li.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.